The company designs, manufactures, and installs architectural aluminum facades, windows, and doors for residential, commercial, and industrial buildings.
The company lacks a durable moat, as evidenced by its negative cash conversion and the commodity nature of aluminum fabrication. While backward integration into powder coating and solar power provides minor cost efficiencies, the low average ROCE of 12.2% suggests a lack of significant pricing power or structural advantage.
Management has focused on vertical integration and capacity expansion, including a recent IPO to fund a new glazing facility. However, the negative cash conversion and high reinvestment requirements have resulted in a reliance on external debt and equity to fund growth.
The company's aggressive growth narrative collapsed when the disconnect between reported accounting profits and persistent negative cash flow became unsustainable. As working capital requirements ballooned alongside revenue, the reliance on external debt to bridge the gap hit a wall when lenders tightened credit following the history of technical defaults. The inability to convert inventory into cash led to a liquidity crunch, forcing fire sales of assets and diluting shareholders to keep the lights on, ultimately proving that the business was merely a furnace for consuming capital rather than a generator of it.
RichFakir rates HRS Aluglaze Ltd's business quality as mediocre — 44/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, HRS Aluglaze Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on HRS Aluglaze Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of HRS Aluglaze Ltd's fair value is about ₹39 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →